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A novel gene cluster allows 
preferential utilization of 
fucosylated milk oligosaccharides 
in Bifidobacterium longum subsp. 
longum SC596
Daniel Garrido1,2,3, Santiago Ruiz-Moyano1,2,†, Nina Kirmiz1,2, Jasmine C. Davis2,4,  
Sarah M. Totten2,4, Danielle G. Lemay2,5, Juan A. Ugalde6, J. Bruce German2,7, 
Carlito B. Lebrilla2,4 & David A. Mills1,2,7
The infant intestinal microbiota is often colonized by two subspecies of Bifidobacterium longum: 
subsp. infantis (B. infantis) and subsp. longum (B. longum). Competitive growth of B. infantis in the 
neonate intestine has been linked to the utilization of human milk oligosaccharides (HMO). However, 
little is known how B. longum consumes HMO. In this study, infant-borne B. longum strains exhibited 
varying HMO growth phenotypes. While all strains efficiently utilized lacto-N-tetraose, certain 
strains additionally metabolized fucosylated HMO. B. longum SC596 grew vigorously on HMO, and 
glycoprofiling revealed a preference for consumption of fucosylated HMO. Transcriptomes of SC596 
during early-stage growth on HMO were more similar to growth on fucosyllactose, transiting later to 
a pattern similar to growth on neutral HMO. B. longum SC596 contains a novel gene cluster devoted 
to the utilization of fucosylated HMO, including genes for import of fucosylated molecules, fucose 
metabolism and two α-fucosidases. This cluster showed a modular induction during early growth on 
HMO and fucosyllactose. This work clarifies the genomic and physiological variation of infant-borne  
B. longum to HMO consumption, which resembles B. infantis. The capability to preferentially consume 
fucosylated HMO suggests a competitive advantage for these unique B. longum strains in the breast-fed 
infant gut.
The human gut microbiome is a complex metabolic ‘organ’ that significantly impacts human health1. The assem-
bly of this ‘organ’ starts immediately after birth, when various microbial clades from different body sites are intro-
duced into the neonate and begin a long-term relationship with the host2. It is generally understood that variables 
such as diet, mode of birth and early-life stresses have a profound influence on the successions of gut microbes 
during the neonatal period3,4. These patterns of colonization, in turn, have been shown by certain studies to 
impact health later in life5. In general, the infant gut microbiome exhibits a characteristic composition during 
nursing often dominated by Bifidobacterium species6 prior to transition into a more adult-like composition of 
species, influenced by the introduction of solid foods7.
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Of special interest is how breastfeeding can shape the gut microbiome of infants. In addition to providing 
critical nutrients and bioactive molecules that support growth and development8,9, breast milk contains complex 
oligosaccharides that escape intestinal enzymes and transit through the gastrointestinal tract of the infant10. Free 
human milk oligosaccharides (HMO) are present in high concentrations in milk8, suggesting that their function 
is important even though they have little nutritional value for the infant. These carbohydrates are far from sim-
ple: they range from 3 to 32 in their degree of polymerization, and are composed of five main monosaccharides: 
D-glucose (Glc), D-galactose (Gal), N-acetylglucosamine (GlcNAc), L-fucose (Fuc) and N-acetylneuraminic (or 
sialic) acid (Neu5Ac). Complexity in HMO lies in the diversity of glycosidic bonds in these molecules, rendering 
a large number of potential combinations11,12. While the total concentration of HMO appears to be tightly regu-
lated, variation in their abundance, is explained in part by host genetic factors8.
In spite of this complexity, a relatively small number of HMO species can represent up to 70% of the 
total12,13, including fucosylated neutral HMO such as 2′ -fucosyllactose (2FL), 3-fucosyllactose (3FL) and 
lacto-N-fucopentaoses12; acidic HMO such as sialyllacto-N-tetraoses, 3′ - and 6′ -sialyllactose (3SL and 6SL)12, and 
neutral non-fucosylated HMO such as lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT) and lacto-N-hexaose 
(LNH)14.
Comparisons of intestinal microbiota of breast-fed and formula-fed infants reveal a strong correlation 
between breastfeeding and the overabundance of Bifidobacterium spp.15. These bacteria can represent up to 90% 
of the total gut bacteria during breastfeeding16, and their abundance decreases later in life15. Bifidobacteria are 
generally recognized as beneficial, with several species currently used in probiotic formulations. Certain bifido-
bacteria are more common in infants, such as Bifidobacterium longum subsp. infantis (B. infantis) and B. breve. 
Other species seem to be present both in the infant and adult gut microbiota, such as B. bifidum, B. pseudocatenu-
latum and Bifidobacterium longum subsp. longum (B. longum)17,18.
B. infantis and B. bifidum have been examined as two different models for milk glycan consumption19. B. infan-
tis internalizes HMO, relying on several ABC transporters with defined specificity for certain HMO families20, 
followed by the action of numerous glycosyl hydrolases to metabolize milk glycans21–24. Recently, select B. breve 
isolates that grow well on HMO were shown to internalize and metabolize complex fucosylated HMO25. In con-
trast, B. bifidum has an array of cell-wall associated glycosyl hydrolases26,27, enabling HMO degradation outside 
the cell and select mono- and disaccharides imported via specific transporters for catabolism28. Notably, the mode 
of consumption by B. bifidum leaves fucose and sialic acid externally, monomers that can subsequently serve as 
growth substrates for other bacteria29–31. Indeed, B. bifidum was recently shown to release mucin-associated sialic 
acid which cross fed B. breve UCC200332.
B. longum strains are also present at high concentrations in the infant gut microbiota15,17. However, several 
genomic and functional studies have indicated this subspecies is more adapted to an adult diet33,34, possessing 
transporters and glycosyl hydrolases active on plant oligosaccharides. Despite membership within the same spe-
cies, genomes of B. longum are notably different from B. infantis35, with the latter possessing a wealth of genes 
associated to consumption of milk glycans, suggesting a lifestyle more adapted to the milk-fed infant gut36.
HMO consumption has only been examined in a few B. longum strains to date, where the consumption pro-
file appears rather restricted by comparison to the B. infantis subspecies37,38. While genomic35 and phenotypic39 
screens of multiple B. infantis strains indicate that strong growth on HMO is a signature of the subspecies, HMO 
consumption is more variable in strains from other bifidobacterial species25. Given the importance of the early 
assembly of the infant gut microbiota on long term health, it is important to understand which microbes are 
uniquely enriched by milk glycans and examine the genetic functions responsible for this enrichment. In this 
study we demonstrate unique genetic loci are responsible for vigorous growth on fucosylated HMO by select iso-
lates of B. longum and present genomic and functional characterization of HMO consumption by a prototypical 
strain, B. longum SC596.
Results
Genetic characterization of B. longum isolates by MLST. In a previous screen of bifidobacterial iso-
lates obtained from breast-fed infants25, 297 B. longum species group isolates were further identified as B. longum 
subsp. infantis or subsp. longum using Multilocus Sequencing Typing (MLST) analysis40. A total of 158 isolates 
were identified as B. infantis and 139 as B. longum by MLST (data not shown). The MLST analysis of this pool of B. 
longum strains resolved into a library of 17 B. longum individual strain types (Table S1). A MLST-based phyloge-
netic tree of these strains combined with additional B. longum isolates obtained from various culture collections 
and other B. longum strains for which a genome sequence was available is shown in Figure S1. Interestingly, four of 
these strains are from adult origin (Table S1), however they were not differentiable from infant strains (Figure S1), 
suggesting infant and adult strains of B. longum are genomically similar. In addition, MLST data suggests that B. 
longum subsp. infantis 157F, a strain that has been shown to inhibit enteropathogenic Escherichia coli in an animal 
model41, is actually a B. longum subsp. longum strain. This is consistent with the 157F genome lacking several gene 
clusters characteristic of B. infantis subspecies33,34.
Physiology of the consumption of HMO in B. longum. To understand the strain-level growth behavior 
of B. longum on HMO, we used HMO purified from pooled breast milk samples, in addition to individual HMO 
structures, as the sole carbon source in growth experiments. The individual HMO structures represent the chem-
ical diversity found in breast milk: LNT, LNnT, 2FL, 3FL, 3SL and 6SL. We also included mucin as a substrate, as it 
has been reported that some B. longum strains can use these glycoproteins as a carbon source42.
Most B. longum strains grew to intermediate levels on HMO (OD600 values (0.5–0.8); Table 1 and Figure S2), 
values which are lower than that obtained by B. infantis37. Growth using specific HMO structures showed impor-
tant differences in HMO utilization among the strains. All strains grew well on LNT (Galβ 1-3GlcNAc linkage; 
Figure S2) as the sole carbon source (Table 1). LNT is the most abundant oligosaccharide in breast milk that 
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supports the growth in vitro of several bifidobacteria38. In contrast, growth of B. longum strains on the isomer 
LNnT (containing a Gal(β 1-4)GlcNAc linkage) was markedly low for most strains, with the exception of SC558 
and SC664 that displayed good growth on this oligosaccharide (Table 1, Figure S2).
Fucosylated HMO represent a large percentage in breast milk, and utilization of these carbohydrates is com-
mon in B. bifidum, B. infantis, and select B. breve strains22,25,38. Using 2FL and 3FL as a carbon source, we found 
that most B. longum strains do not grow on these substrates (Table 1). However, B. longum strain SC596 exhib-
ited vigorous growth on 2FL and 3FL, reaching maximum OD600 values considerably higher than B. infantis 
(Fig. 1A,B).
None of the B. longum strains were able to grow on 3SL or 6SL as a sole carbon source (Table 1, Figure S2). 
In contrast, several strains grew at lower levels on mucin as the sole carbon source, higher than B. animalis but 
not similar to known mucin-degrader B. bifidum PRL201028 (Table 1 and Figure S2). Strain SC215 displayed 
higher OD than any other B. longum isolate on this substrate (Figure S2). Mucin appears to be preferentially 
used by several B. bifidum strains28, and several B. longum and B. bifidum strains have been shown to encode 
endo-α -N-acetylgalactosaminidases42,43, enzymes that can release O-linked glycans from intestinal mucins.
Maximum growth OD600 values for each B. longum strain on each substrate were examined via principal com-
ponent analysis (PCA; Figure S3). PCA1 and PCA2 explain 53.59% and 21.12% of data variation, respectively. 
This analysis indicates that in general the patterns of utilization of LNT, LNnT, and mucin were the most diverse 
among B. longum. The second part of the plot shows that strain SC596 is rather divergent from the rest of strains, 
which is probably due to its better growth on several classes of HMO. In contrast, strain SC249 showed poor 
growth on all substrates tested and also appeared distant from the other strains. In summary, the ability of B. 
longum to grow on individual HMO appears strain-specific, with several novel strains consuming complex HMO.
Glycoprofiling of the HMO consumption. To better understand HMO consumption preferences, mass 
spectrometry-based glycoprofiling was run on strains that displayed better growth on HMO (SC215, SC596, 
SC558, SC618 and SC697; Table 1), with B. longum DJO10A as a control. Accounting for total HMO consump-
tion, percentages were rather low, varying from 15 to 30% for strain SC596 (Fig. 2A). B. longum DJO10A and 
JCM1217 have been the only strains of this subspecies previously tested for HMO growth, and their low con-
sumption is in agreement with these results (Fig. 2A). Utilization of fucosylated HMO was significantly higher for 
strain SC596 (30%), with consumption also observed for strains SC215 and SC558 (Fig. 2B).
Details on specific HMO structure consumption are shown in Fig. 3, and detailed HMO compositions are 
shown in Table S2. All strains tested completely consumed LNT (and/or its isomer, LNnT, which cannot be 
resolved from the analysis), in agreement with the idea that LNT is a preferred substrate for B. longum. Strain 
SC215 was unique in that it could ferment LNH, its isomer p-LNH, and sialyl-LNH (Fig. 3A) as well as several 
larger, complex fucosylated HMO (Fig. 3B). The ability of SC215 to degrade complex fucosylated HMO is inter-
esting considering this strain cannot use 2FL as a growth substrate (Figure S2). In agreement with the FL growth 
phenotype, B. longum SC596 completely depleted 2FL, LNFP and LDFT from the HMO pool (Fig. 3B).
Complex Milk Sugars
Strains HMO LNT LNnT 2FL 3FL 3SL 6SL Mucin LAC
SC91 + + a + + + + − − − − + + + + 
SC116 + + + + + + − − − − + + + + 
SC156 + + + + + + + − − − − + + + + 
SC215 + + + + + − − − − − + + + + 
SC249 − − − − − − − − − 
SC280 + + + + + + − − − − + + + + 
SC513 + + + + + − − − − + + + + 
SC536 + + + + − − − − − − + + + 
SC558 + + + + + + + + − + − − + + + + 
SC592 + + + + + + − − − − − + + + 
SC596 + + + + + + + + + + + + + − − + + + + 
SC618 + + + + + + + − − − − − + + + 
SC630 + + + + + + + − − − − − + + + 
SC657 + + + + − − − − − − + + + 
SC662 + + + + − − − − − − + + + 
SC664 + + + + + + + − − − − + + + + 
SC697 + + + + + − − − − − + + + + 
ATCC 15697 + + + + + + + + + + + + + + + + + + + + − + + + 
PRL2010 ndb nd nd nd nd nd nd + + + + 
JCM10602 − − − − − − − − + + 
Table 1.  Growth of infant-associated B. longum strains on different complex sugars associated with human 
milk. aLevel of growth was classified as follows: − , negative (maximum OD600 < 0.2); + , low (OD600 from 
0.2 to 0.5); + + , moderate (OD600 from 0.5 to 0.8); + + + , high (OD600 > 0.8). bnd: not determined Control 
strains; B. infantis ATCC15697, B. bifidum PRL2010 and B. animalis subsp. lactis JCM10602 are also shown.
www.nature.com/scientificreports/
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Temporal glycoprofiling of HMO by SC596 revealed fucosylated HMO are utilized first, with 2FL and LDFT 
reaching 100% consumption during mid exponential growth (Fig. 2C). In contrast, neutral HMO like LNT were 
depleted only in late exponential phase. Utilization of LNFP I and III followed a similar pattern as LNT and con-
sumption of other HMO did not show any temporal preference. In aggregate, these results indicate that specific 
infant B. longum strains consume fucosylated HMO, and that one strain actually has a preference for fucosylated 
HMO over neutral oligosaccharides.
Genome sequencing of B. longum SC596. Due to the increased consumption of fucosylated HMO by 
B. longum SC596, a draft genome sequence was generated in order to identify key genes linked to this enhanced 
HMO consumption. To sequence SC596, 45 million reads with HiSeq Illumina sequencing (100 bp paired 
ends, coverage 800X) were generated, and the Integrated Microbial Genome Expert Review annotation plat-
form (https://img.jgi.doe.gov, GOLD Project ID: Gi17164), was used for annotation and deposition. The SC596 
genome assembled into 50 contigs, with an average of 52092 bp per contig. Genome size was 2.602 Mb, with a 
G + C content of 59.93%.
Comparative genomics of subsp. longum. The genome of B. longum SC596 contains a variety of genes 
associated with oligosaccharide utilization (Table S3). In particular, B. longum SC596 was found to contain two 
genes encoding α -fucosidases, similar to B. longum strains CMCC P0001 and JDM301 (Table S3). These three 
Figure 1. Growth of B. longum isolates on mMRS medium supplemented with 2% 2FL (A) or 3FL (B). Growth 
was measured as OD of the media at 600 nm. Fermentations were carried out in triplicate; controls consisted of 
inoculated medium lacking of substrates and un-inoculated medium containing a substrate which was also used 
as blank for OD measurements. Bi: B. infantis, Bal: B. animalis.
www.nature.com/scientificreports/
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same strains also possessed an overabundance of the COG1653 (Family 1 Solute Binding Proteins) compared to 
other B. longum genomes (Table S3). These proteins are the binding component of ABC transporters for oligosac-
charides. These observations initially suggest that SC596 has an additional preference for complex oligosaccha-
rides by comparison to the other B. longum strains.
Phylogenomic level comparison of B. longum genomes suggest strain SC596 is more related to strains from 
adult origin, than other infant strains (Figure S4). Comparative genomics also confirm that B. longum 157F 
belongs to the subspecies longum and that B. longum JDM301 forms a different cluster—observations which are 
in agreement with the MLST data (Figure S1) and previous B. longum pangenome analysis34. B. longum DJO10A, 
a strain from adult origin and one of the most studied in the species longum, does not grow well on HMO37. A 
direct comparison of DJO10A and SC596 (Figure S5) revealed genes unique to each strain suggesting differential 
adaptations. For example, strain SC596 contains a complete cluster for exopolysaccharide biosynthesis, which 
is absent in DJO10A. It also contains a two-component system and a potassium channel with a putative role in 
osmoregulation (data not shown). Strain SC596 also possesses several other ABC transporters for oligosaccha-
rides compared to DJO10A. Genes from DJO10A plasmids, pDOJH10-L and pDOJH10-S, were absent in strain 
SC596, as well as a gene encoding a NADPH-quinone reductase.
Global transcriptomics of B. longum SC596 during growth on HMO. The transcriptomic response 
of SC596 on HMO was explored in two sets of experiments. SC596 was grown on HMO purified from pooled 
breast milk samples as the sole carbon source, and samples were taken at four time points during exponential 
phase (early, mid1, mid2 and late exponential, see materials and methods). These samples match those used for 
glycoprofiling described above. In addition, B. longum SC596 was grown to mid exponential phase on select indi-
vidual HMO: LNT, LNnT, 2FL and 3FL. Samples taken during growth on lactose were used as a reference control, 
given that this sugar is the structural precursor of all HMO, and that B. longum uses lactose instead of glucose as 
the preferential carbon source44,45.
Over 163 million 50 bp reads were generated from 36 independent RNA-seq experiments with an average of 
9.09 million reads per sample using Illumina HiSeq (Table S4). Of these, 76.6% aligned to coding genes, with an 
11.6% aligning to intergenic regions. 16S and 23S transcripts represented in average 0.9% and 2.3% of the total 
sequences. Other features and statistics of these experiments are shown in Table S4.
Figure 2. Glycoprofiling of the HMO consumption by select B. longum strains. (A) Total utilization of 
HMO; (B) Total fucosylated HMO consumption. Bacteria were incubated with pooled HMO from breast milk 
and consumption was calculated as the percent difference in HMO between the start and the end of exponential 
phase. (C) Temporal glycoprofile of the consumption of select neutral and acidic HMO by B. longum SC596 at 
different phases during the exponential phase. Error bars represent experiments in triplicate.
www.nature.com/scientificreports/
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All datasets were first compared among each other. The heatmap in Fig. 4 shows the Euclidian distances 
between the whole transcriptome of each sample. This analysis shows that all replicates are most similar to each 
other. Interestingly, global responses of B. longum SC596 to 2FL and 3FL were very similar and more related to 
lactose than any HMO time point. Transcriptomes from the early and mid1 time points during growth on HMO 
clustered closer to lactose and FLs, while mid2 and late HMO time points appeared more similar to LNT and 
LNnT. Out of all the substrates, the HMO early and late time points were the most different (Fig. 4), suggesting a 
large change in transcriptional state in strain SC596 during growth on HMO, complementing the progression in 
oligosaccharide preferences depicted in Fig. 2C.
Differentially Expressed Genes. A large number of genes were differentially regulated by each treatment rela-
tive to lactose (Tables S5, S6 and S7). These genes were classified by their log2foldchange relative to lactose, and 
Figure 3. Glycoprofiling HMO consumption on select B. longumw strains. (A) Percentage of utilization of 
neutral HMO; (B) Percentage of utilization of fucosylated and sialylated HMO. Bacteria were incubated with 
pooled HMO from breast milk and consumption was calculated as the percent difference in HMO between the 
start and the end of exponential phase. Error bars represent experiments in triplicate.
www.nature.com/scientificreports/
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analyzed using Gene Set Enrichment Analysis. Functional annotations tested included COG functions, KEGG 
pathways, GO terms, and SRI pathways.
Functional enrichment results for genes up- and down-regulated relative to lactose are summarized in Tables 
S5 and S6, respectively. Several gene categories related to translational processes were significantly up-regulated 
at the early HMO points. Categories such as ATPases of ABC transporters and carbohydrate transport were 
upregulated during growth on certain HMO species. Interestingly, growth on HMO also induced xylan utilization 
genes (Table S6). Other evidence has indicated a role for this pathway in utilization of host-derived glycans by B. 
bifidum28.
Functional transcriptomics of HMO utilization in B. longum SC596. Integration of genomic information and 
transcriptomic profiles during growth on pooled HMO or single HMO molecules allowed identification of sev-
eral clusters likely responsible for the unusual HMO consumption phenotype of SC596. To complement these 
observations, we examined the biological function of the ABC transporters and enzymes in these clusters, by 
using a mammalian glycan array to determine the affinities of the transporters or mass spectrometry to determine 
the specificities of glycosyl hydrolases for HMO.
B. longum LNB/GNB cluster. Most bifidobacterial genomes studied to date contain a cluster devoted to the 
import and processing of type 1 HMO (termed the LNB/GNB cluster46, Figure S6). This cluster contains an ABC 
importer for LNT and other HMO containing the Galβ 1-3GlcNAc/GalNAc linkage20, and a Leloir-like path-
way that further process galactose and GlcNAc/GalNAc into the bifid shunt47. In SC596 all genes in this cluster 
(BLNG_00160-00166; Table S8) were induced several fold during growth on HMO, suggesting their participation 
in HMO metabolism (Fig. 5). These genes were also induced several fold during growth on LNT and LNnT as 
well. However, levels of expression were low during growth on lactose, 2FL or 3FL, which is in agreement with the 
idea of their specific role in metabolism of HMO containing the Galβ 1-3GlcNAc linkage.
Solute Binding Proteins (SBPs) are a major determinant of specificity in the import of complex oligosac-
charides in bifidobacteria20. The SBP BLNG_00160 in the LNB/GNB cluster binds linkages with Galβ 1-3 (Galβ 
1-3Gal/GlcNAc/GalNAc; Table 2), as found in LNT, Galacto-N-tetraose (GNT), LNB and GNB. In addition, 
BLNG_00160 showed high affinity for other structurally related glycans, such as sialyl LNT, LNT, and even several 
complex bi- and tri-antennary N-glycans (Table 2). Several milk and intestinal glycoproteins contain N-glycans, 
which have been thought to be potential carbon sources for intestinal bifidobacteria48.
A second ABC transporter (BLNG_00933-00936; Figure S6) was also induced up to 300 fold during growth 
on HMO, however only at later time points (Fig. 5). This cluster was also highly expressed during growth on 
LNT and LNnT again, suggesting a linkage to the LNT consumption preferences witnessed in Fig. 2C. The glycan 
specificity of the SBP in this cluster (BLNG_00936) is oriented toward oligosaccharides with Galβ 1-3 as common 
motif (Galβ 1-3GalNAc, GNB and Galβ 1-3Galβ 1-4GlcNAc), albeit via weak binding (Table 2).
Figure 4. Global transcriptome distances in substrate responses of B. longum SC596 to human milk 
oligosaccharides. The heatmap shows the distances between the whole transcriptomes in response to LNT, 
LNnT, lactose (LAC), 2FL, 3FL, and four time points during HMO growth (early, mid1, mid2, late). Each 
experiment on each substrate was done in duplicate (i.e. samples ‘A’ and ‘B’). Branches represent the Euclidean 
distances of the whole transcriptomes after variance-stabilization of the count data. The intensity of the blue 
color in the heatmap indicates the degree of similarity, from white (dissimilar) to dark blue (most similar). 
Likewise, the dendograms also show the distances with larger branch lengths indicating greater distances.
www.nature.com/scientificreports/
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B. longum β-galactosidases. In general, β -galactosidases active on HMO have a preference for either type 1 
(Gal(β 1-3)GlcNAc), or type 2 (Gal(β 1-4)GlcNAc) linkages found in HMO21. In B. longum SC596 only two genes 
encoding β -galactosidases (BLNG_00015, BLNG_01753) were expressed at considerable values at all conditions 
assessed in this study (Fig. 5, Table S8). BLNG_00015 belongs to the carbohydrate active enzyme (CAZY) family 
GH2 while BLNG_01753 is a member of the GH42 family (Table S8). Neither enzyme appeared to be extracellular 
since they lack transmembrane domains or signal peptide sequences. Their amino acid sequences share more 
than 95% identity with Blon_2334 and Blon_2016 (respectively) from B. infantis ATCC 15697; previously studied 
enzymes that display high efficiency towards lactose and LNnT (type 2; Blon_2334), and LNT-like HMO (type 1; 
Blon_2016)21,49.
Considering that all substrates used in transcriptome profiling contain a terminal lactose, it is not unexpected 
that BLNG_00015 displayed high expression values on all substrates used and at any time point during growth 
on HMO (with a decrease at the late-exponential phase; Fig. 5). Purified BLNG00015 enzyme exhibited maximal 
activity at pH 6.0 and 55 °C. This enzyme appeared to be specific for type 2 linkages releasing galactose from 
lactose and LNnT (TLC results, data not shown). Mass spectrometry was also used to detect the activity of this 
enzyme previously incubated with HMO purified from breast milk (Fig. 6). BLNG00015 displayed a general 
preference for terminal β 1-4 linkages, as found in LNH, LNnH, and other more complex oligosaccharides up to 
10 residues, although the enzyme reduced the concentration of several other HMO (Fig. 6).
A second β -galactosidase involved in HMO degradation in B. longum SC596 is BLNG_01753, a GH42 family 
enzyme. Expression of BLNG_01753 displayed medium RPKM values (150–500 RPKM) across all substrates, but 
with increasing values toward later time points during growth on HMO. This observation correlates with neutral 
HMO being fermented after fucosylated HMO observed during the temporal glycoprofiling (Fig. 5). Purified 
BLNG01753 has an optimum pH of 5.5 and 55 °C, similar to what has been found in its homolog in B. infantis49. 
Mass spectrometry-based analysis of HMO cleavage products revealed BLNG01753 displayed a general prefer-
ence for type 1 HMO species as found in LNT, LNH, DFpLNH II and DFLNO I (Fig. 6). Together, these data indi-
cate that neutral HMO are metabolized by B. longum SC596, with features that resemble more of the B. infantis 
strategy for HMO consumption (import of HMO and intracellular degradation mediated by SBPs) than that of B. 
bifidum (extracellular degradation and import of mono and disaccharides19).
B. longum FHMO cluster. Strain consumption data described above revealed that SC596 has a preference for 
fucosylated HMO such as 2FL and LNFP. Genome analysis and RNA-seq revealed a prominent gene cassette in 
SC596 that was absent in DJO10A, a strain that does not consume fucosylated oligosaccharides (Fig. 7 ref. 37). 
This cluster, termed FHMO (Fucosylated Human Milk Oligosaccharides utilization cluster) comprises genes 
BLNG_01254 to BLNG_01264, encoding a LacI-like transcriptional regulator, an ABC transporter, an SBP and 
ABC permease system, putative fucose metabolism genes and two α -fucosidases (Fig. 7).
Figure 5. Hierarchical clustering of features of carbohydrate metabolism genes induced in B. longum 
SC596 during growth on HMO used in this study (See Table S7). Heat map shows intensity of these genes in 
response to LNT, LNnT, lactose (LAC), 2FL, 3FL, and four time points during HMO growth (early, mid1, mid2, 
late). Each experiment on each substrate was done in duplicate (i.e. samples ‘A’ and ‘B’). Clustering is calculated 
according to RPKM values for each gene.
www.nature.com/scientificreports/
9Scientific RepoRts | 6:35045 | DOI: 10.1038/srep35045
The putative SBP in the FHMO cluster, BLNG_01257, provides the glycan specificity to the ABC cassette. 
Purified BLNG01257 bound strongly to Fuc(α 1-2)Gal, the H-antigen precursor in ABO glycans, and also a com-
mon epitope in milk oligosaccharides (Table 2). This SBP was also able to recognize 2FL and Fuc (α 1-2) Gal 
(β 1-4) GlcNAc(β 1-3) GalNAc. BLNG_1257 is homolog to Blon_0343 and Blon_2202 in B. infantis, SBPs that 
display identical ligand affinities for small fucosylated HMO20.
The two α -fucosidases present in the FHMO cluster (BLNG_01263 and BLNG_01264, Fig. 7) appear to be 
intracellular enzymes, given the lack of transmembrane domains or signal peptide sequences. Recombinant 
BLNG01263 displayed a preference for α (1–3/4) Fuc linkages, digesting HMO up to 10 residues such as IFLNH 
III, MFpLNH IV and DFLNO I and II (Fig. 6). These results resemble α -fucosidase Blon_2336, a close homolog 
found in B. infantis ATCC 1569722. The second α -fucosidase on this cluster, BLNG_01264, shares a 77% identity 
with Blon_2335 in B. infantis22. Purified BLNG01264 was shown to digest α (1–2) fucosyl linkages, however it 
also cleaved certain HMO with a α (1–3) Fuc linkage (Fig. 6). For example, it removed nearly 100% 2′ FL, LDFT, 
LNFP and DFLNHa, all containing an α (1–2) fucosyl linkages. Interestingly, the specificities of BLNG_01263 
and BLNG_01264 are highly complementary, indicating that expression of both enzymes possibly renders 100% 
consumption for most fucosylated HMO (Fig. 6).
All the genes within the FHMO cluster were expressed in a coordinated fashion across all conditions suggesting 
a single transcriptional unit (Fig. 5). Expression of the FHMO cluster was induced nearly 100 fold relative to lactose 
during growth on 2′ FL or 3FL (Fig. 5) however the cluster was not expressed during growth on lactose, LNT or 
LNnT, substrates not containing fucose. Induction of the cluster peaked during growth at earlier time points during 
growth on HMO, returning to basal levels in late exponential phase. This observation correlates with the preferential 
consumption of fucosylated HMO by B. longum SC596 by comparison to neutral HMO (Fig. 2C).
An examination of other sequenced B. longum strains identified similar FHMO clusters in two B. longum 
strains, one of them isolated from a healthy infant (Fig. 7; ref. 50). Interestingly, the FHMO cluster found has 
significant homology to two ABC transporters in B. infantis (Blon_0341-0343 and Blon_2202-2204), and part of 
the well-described HMO cluster I in B. infantis (Fig. 7; ref. 33).
Discussion
Bifidobacteria are important members of the intestinal microbiome in both infants and adults4. HMO and other 
milk glycoconjugates are considered the primary substrates for enrichment of these species in the infant gut. 
Previous genomic evidence suggests that B. infantis co-evolved with mammalian milk glycans via a complement 
of genes that allow the strains to be competitive in consumption of HMO in the neonate gastrointestinal tract33. 
These genetic determinants, forming discrete gene clusters in B. infantis, are mostly absent in B. longum strains of 
adult origin35. Indeed, B. longum isolated from adults has been usually regarded to be more competitive on plant 
B. longum SC596 SBP gene and glycan structure bound Average RFUb
BLNG_00160
 Galβ1-3Galβ 1-4GlcNAcβ -Sp8 4654
 Galβ1-3GalNAcβ1-4Galβ 1-4Glcβ -Sp8 3430
 Galβ1-3GlcNAcβ1-3Galβ 1-4GlcNAcβ 1-6(Galβ1-3GlcNAcβ1-3Galβ 1-4GlcNAβ 1-2)Mana1-6 
 (Galβ1-3GlcNAcβ1-3Galβ 1-4GlcNAcβ 1-2Mana1-3)Manβ 1-4GlcNAcβ 1-4(Fuca1-6)GlcNAcβ -Sp24 3351
 Neu5Acα 2-6(Galβ1-3)GlcNAcβ 1-4Galβ 1-4Glcβ -Sp10 2706
 Galβ1-3(6S)GlcNAcβ-Sp8 2646
 Galβ1-3GalNAcβ1-3Gal-Sp21 2528
  Galβ1-3GlcNAcβ1-3Galβ 1-4GlcNAcβ 1-3Galβ 1-4GlcNAcβ 1-6(Galβ1-3GlcNAcβ1-3Galβ 1-4GlcNAcβ 1-3Galβ 
1-4GlcNAβ 1-2)Mana1-6(Galβ1-3GlcNAcβ1-3Galβ 1-4GlcNAcβ 1-3Galβ 1-4GlcNAcβ 1-2Mana1-3)Manβ 1-4GlcNAcβ 
1-4(Fuca1-6)GlcNAcβ -Sp24
2513
 Galβ1-3GalNAcβ-Sp8 2338
 Galβ1-3GlcNAcβ1-3Galβ 1-4GlcNAcβ 1-6(Galβ1-3GlcNAcβ1-3)Galβ 1-4Glcβ -Sp0 2212
  Galβ1-3GlcNAcβ1-3Galβ 1-4GlcNAcβ 1-2Mana1-6(Galβ 1-3GlcNAcβ 1-3Galβ 1-4GlcNAcβ 1-2Mana1-3)Manβ 
1-4GlcNAcβ 1-4GlcNAc-Sp25 2079
 Galβ1-3GlcNAcβ1-3Galβ 1-4GlcNAcβ -Sp0 2029
 Galβ1-3GlcNAcβ1-3Galβ 1-4Glcβ -Sp10 1784
 Galβ1-3Galβ-Sp8 1508
 Galβ1-3GlcNAcβ-Sp0 969
BLNG_00936
 Galβ1-3GalNAcβ-Sp8 303
 Galβ1-3Galβ1-4GlcNAcβ -Sp8 126
BLNG_01257
 Fuca1-2Galβ-Sp8 2161
 Fuca1-2Galβ1-4Glcβ -Sp0 360
Table 2.  Binding affinities of B. longum SC596 encoded Solute Binding Proteins for mammalian glycans. 
In bold are shown common motifs recognized by any SBP. Spacers (Sp) are repeats of CH = CH units to a glass 
slide in the Glycan Array, and can contain repeats from 0 to 25 units. RFU: Relative fluorescence Units.
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oligosaccharides51. In this study, we determined that select B. longum strains can robustly consume HMO and 
identified and characterized gene clusters associated with this activity in strain SC596.
The HMO utilization in B. longum has only been addressed in a few adult-derived strains: DJO10A, JCM1217 
and ATCC 1570737,38,52. These strains exhibited poor HMO metabolism, only consuming LNT from the pool 
HMO species present in human milk. In this study, we isolated and characterized a larger panel of infant-derived 
B. longum strains, and demonstrated more variation in growth on HMO. In addition to LNT utilization, which 
is mostly conserved in infant and adult-borne bifidobacteria, we found a B. longum strain displaying vigorous 
growth on LNnT (SC664, Figure S2). In addition to B. longum SC596 (that was further characterized in this 
study), strain SC215 displayed also a very competitive phenotype in HMO utilization in addition to mucin 
growth. This strain was unique in that it consumed neutral hexaoses such as LNH and p-LNH (Fig. 3), and sev-
eral fucosylated HMO such as MFpLNH IV, 5130 a, 5130 b and DFLNO I (Fig. 3 ref. 12). The inability of SC215 to 
grow or consume 2FL, compared to more complex fucosylated HMO, suggests that 2FL is imported by different 
transporters. Moreover, SC215 also consumed vigorously sialyl-LNH (Fig. 3). While we did not find any evidence 
for sialidase activity on this strain, it is possible that this oligosaccharide is still imported and the neutral part of 
the molecule might be utilized. In aggregate, these observations allow us to conclude that HMO utilization is also 
variable in B. longum, similar to what has been observed for B. breve and B. bifidum25,53, and in contrast with B. 
infantis strains that display a very consistent consumption of major types of HMO37.
B. longum SC596 was able to grow vigorously on 2FL and 3FL to higher OD600 values than reference strain B. 
infantis ATCC 15697. When growing on pooled HMO, SC596 exhibited a clear preference for fucosylated HMO 
such as 2FL and LNFP, while consuming neutral HMO later during in vitro growth. Temporal glycoprofiling has 
shown different results among bifidobacteria. While B. infantis does not exhibit a preference for any neutral or 
fucosylated HMO consuming several HMO simultaneously22, specific B. breve strains are able to deplete sialylated 
HMO before reaching full consumption of neutral HMO such as LNT25. The genetic control mechanisms respon-
sible for these different HMO species preferences are yet unknown, however the presence of LacI-like transcrip-
tional regulators in several of the clusters described suggests they control the hierarchy in HMO utilization.
Whole transcriptomes of B. longum SC596 during exponential growth on HMO were largely divergent, indi-
cating a large transcriptional change in SC596 as different HMO species were catabolized (Fig. 4). Such transition 
was not previously noted in B. infantis HMO-transcriptomes53, which were rather stable during growth, or B. 
bifidum SC555, where HMO-transcriptomes were similar to neutral HMO (LNT and LNnT). The latter strain 
focused its metabolism in this class of HMO rather than sialylated or fucosylated HMO53.
Figure 6. Heat map of the digestion of individually-quantified oligosaccharides from pooled HMO, 
by β-galactosidases (BLNG00015 and BLNG01753) and α-fucosidases (BLNG01263 and BLNG01264) 
purified from B. longum SC596). Enzymes were incubated with pooled HMO and products were quantified 
using LC-MS. The percentage digestion calculated for each of the specific oligosaccharide degraded by these 
enzymes is expressed via a heat map. HMO names and structures were reported in ref. 12. T: Terminal linkage; 
endo: internal linkage.
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SC596 transcriptomes during growth on 2FL and 3FL were more similar to those observed at the early stages 
of growth on HMO, which is in agreement with the observed preference for fucosylated HMO determine by gly-
coprofiling and the induction of the FHMO cluster. Similarly, SC596 transcriptome transition in late exponential 
growth on HMO to a pattern similar to growth on LNT and LNnT, is again indicative of the prioritization of 
fucosylated oligosaccharides by SC596 over neutral HMO species.
Genomic and transcriptomic analyses helped identify the genetic loci putatively responsible for growth of B. 
longum SC596 on HMO. HMO utilization strategies in SC596 appear to occur via a mechanism that seems very 
similar to B. infantis ATCC 15697, which is based on the activity of several ABC transporters for HMO and intra-
cellular glycosyl hydrolases. For example, the SBP in the LNB/GNB cluster (BLNG_00160) from SC596 displayed 
similar affinities for type 1 HMO as its homologs in B. infantis and B. longum strains20,54. Growth on HMO and 
other single HMO species led to a high expression of β -galactosidases and α -fucosidases that are genetically and 
functionally similar to previously characterized enzymes in B. infantis ATCC 1569722,49. One important conse-
quence of this mode of consumption is that does not allow cross-feeding with other gut species, since oligosaccha-
rides are imported inside the cell with each monosaccharide being fermented intracellularly.
Although full expression of the LNB/GNB cluster occurred during late exponential phase growth on HMO 
in addition to LNT and LNnT, it is yet unclear how LNT is metabolized. The activation of the LNB/GNB cluster, 
in particular genes encoding lacto-N-biose phosphorylase, N-acetylhexosamine 1-kinase and GalE and GalT 
(Fig. 5 and Table S8), indicates that LNB is actively metabolized into the Leloir pathway47. How LNB is formed 
and is taken inside the cell is not yet clear. One possibility is that a membrane-bound lacto-N-biosidase cleaves 
LNT into LNB and lactose. However, SC596 does not appear to possess any homolog for this enzyme. It has been 
recently found that B. longum JCM1217 encodes a novel membrane lacto-N-biosidase55, which is enzymatically 
different from the enzyme previously characterized in B. bifidum56. This enzyme was not found in other B. longum 
genomes examined in this study excepting strain BBMN68.
Alternatively, degradation of neutral HMO could be sequential, using exo-acting glycosyl hydrolases. The 
activities of β -galactosidases and β -hexosaminidases release Gal, Glc and GlcNAc. While a β -hexosaminidase in 
SC596 displayed medium-low RPKM values across substrates (BLNG_00911; RPKM~100), expression data sug-
gests that GlcNAc is metabolized in B. longum SC596 by two major enzymes: N-acetylglucosamine-6-phosphate 
deacetylase and glucosamine-6-phosphate isomerase (BLNG_00457 and BLNG_00458). The respective genes are 
located in a cluster together with a transcriptional regulator (BLNG_00459) and a sugar kinase (BLNG_00460; 
Figure S6); a homolog of a similar gene in B. infantis we previously hypothesized activates GlcNAc to GlcNAc-
6-P24. BLNG_00457 and BLNG_00458 increase their expression 45–50 times during growth on HMO, LNT or 
LNnT relative to lactose, 2FL or 3FL. The putative sugar kinase (BLNG_00460) also displays a 10-fold increase in 
its expression on these substrates (Fig. 5).
One striking difference between B. longum strains that do not grow well on HMO (such as DJO10A) and 
SC596 was the presence of the FHMO cluster. Affinities of the cognate SBP, and specificities of the two encoded 
α -fucosidases from this cluster clearly indicated their involvement in consumption of fucosylated HMO. In 
Figure 7. FHMO utilization cluster in B. longum SC596, and homologous genes in bifidobacteria. Arrows 
represent genes, and numbers on top of each gene indicate the locus tag number in the respective genome. 
Text inside the arrows indicates predicted or validated annotations. Red numbers indicate percent identity 
between corresponding genes and homologs relative to strain SC596. Colors of each gene are indicative of the 
primary function of each respective gene: transcriptional regulators (black), oligosaccharide transport (blue), 
carbohydrate feeder pathways (green) and glycosyl hydrolases (red). SBP: Solute Binding Protein; L-Fuc DH: 
L-fuconate dehydrogenase; DHPS: Dihydropicolinate synthase; FucU: L-fucose mutarotase.
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addition, the FHMO cluster was expressed as an HMO-inducible unit, in a modular fashion on fucosylated sub-
strates and not during growth on neutral HMO. Fucose is a key monosaccharide characteristic of host-derived 
glycans, and it plays roles in pathogenesis and serves as a carbon source for certain gut microbes57. For example, 
Bacteroides thetaiotaomicron α -fucosidases release fucose in the gut environment rendering it available for other 
bacteria58. How fucose is metabolized in bifidobacteria is yet unclear however, the high expression of putative 
fucose metabolizing enzymes (Fig. 5; Table S8) suggest that fucose is used as a carbon source in bifidobacteria 
endowed with this pathway.
The FHMO cluster in B. longum SC596 displays some similarities with the HMO cluster I from B. infantis 
(BLNG_01258 to BLNG_01264; ref. 33), with nearly identical fucose metabolism genes and α -fucosidases 
(Fig. 7). Moreover, the FHMO cluster displays homology with two ABC cassettes (SBPs and permeases) found 
in other regions of the ATCC 15697 genome, that putatively import 2FL and Fuc(α 1-2)Gal20. This suggests that 
these clusters are genetically related, however establishing ancestry is difficult given the relatedness of the strains. 
Considering that the intact HMO cluster I appears to be conserved within B. infantis33,35, it is tempting to hypothe-
size that portions of the HMO cluster I transferred to select B. longum isolates residing in the infant gut microbiota.
Conclusion
In this work we examined a panel of B. longum isolates of infant origin to determine the physiological and genetic 
variation for HMO consumption. Unlike B. infantis, the growth phenotype of infant-borne B. longum strains on 
HMO appears variable and only select strains are capable in consuming large, complex HMO species. Further 
characterization of a B. longum strain that grows well on fucosylated HMO revealed a unique preference for 
these structures over neutral HMO. Genomic analysis identified key gene clusters linked to fucosylated HMO 
consumption, resembling cognate genes in B. infantis ATCC 15697, however B. longum SC596 displayed a unique 
and modular induction of HMO utilization genes. The characterization of B. infantis19, B. breve25 and B. longum 
isolates with unique HMO consumption preferences suggests a complementary strategy for survival in the nurs-
ing infant gut whereby different species and subspecies may be able to gain an advantage by more effectively 
consuming a targeted portion of the HMO repertoire delivered to the infant colon.
Methods
Bacteria and media. Bifidobacterium strains used in this study (Table S1) were previously obtained from 
fecal samples from exclusively breast-fed term infants and deposited in the UC Davis Viticulture & Enology 
Culture Collection (Davis, CA25). Bacteria were also obtained from the Japanese Collection of Microorganisms 
(Riken Biosource Center Japan), the American Type Culture Collection (Manassas, VA). For routine experiments, 
bifidobacteria were grown on de Man-Rogose-Sharp (MRS) broth supplemented with 0.05% w/v L-cysteine 
(Sigma-Aldrich, St. Louis, MO), and incubated for 18 h at 37 °C in an anaerobic chamber (Coy Laboratory 
Products, Grass Lake, MI), in an atmosphere containing 5% carbon dioxide, 5% hydrogen, and 90% nitrogen. 
Prior to each assay all bacteria were subcultured twice.
Multilocus sequence typing (MLST) of strains. MLST analysis of B. longum strains targeted intragenic 
regions of seven housekeeping genes clpC, purF, gyrB, fusA, Iles, rplB, rpoB were selected based on a previous 
study25. PCR amplification and analysis was carried as in ref. 25. Cycling conditions were optimized for every 
primer set (Table S9). Sequencing was performed on an ABI 3730 Capillary Electrophoresis Genetic Analyzer 
using BigDye Terminator chemistries at the University of California Davis DNA Sequencing Facility. Sequencing 
data for all loci was edited using BioEdit 7.0 and aligned using CLUSTAL W59. Phylogenetic analysis and con-
catenations of the sequenced loci were performed using the Molecular Evolutionary Genetic Analysis (MEGA) 
software version 5 (http://megasoftware.net). Descriptive evolutionary analysis including mol % G + C content, 
number of polymorphic sites, nucleotide diversity π /site, average number of nucleotide differences k were calcu-
lated using DnaSP version 5.10. Allelic sequences were assigned as described previously55. A minimum evolution 
tree of the concatenated loci was calculated using MEGA 5.0 (Figure S1).
Bifidobacterial growth in vitro on HMO. The 17 B. longum strains in Table S1 were tested for growth 
in the presence of seven different substrates as the sole carbon source: HMO from pooled breast milk60, LNT, 
lacto-N-neotetraose (LNnT), 2′ -fucosyllactose (2FL), 3-fucosyllactose (3FL) (generously provided by Glycom, 
Denmark), 6′ -sialyllactose (6′ SL) (generously provided by GenChem Inc. Korean), and hog mucin type II 
(Sigma). B. animalis subsp. lactis JCM 10602 was also included as negative control and B. infantis ATCC 15697 
and B. bifidum PRL2010 as positive controls for growth experiments. Two μ l of each resulting overnight culture 
were used to inoculate 200 μ l of modified MRS medium (mMRS), devoid of glucose and supplemented with 2% 
(w/v) of each substrate, except for mucin at 1%, as the sole carbohydrate source, and another 2 μ l inoculated into 
mMRS without added sugar. The media was supplemented with 0.05% (w/v) L-cysteine, and in all the cases the 
cultures in the wells of the microtiter plates were covered with 30 μ l of sterile mineral oil to avoid evaporation. 
The incubations were carried out at 37 °C in an anaerobic chamber (Coy Laboratory Products, Grass Lake, MI). 
Cell growth was monitored in real time by assessing optical density (OD) at 600 nm using a BioTek PowerWave 
340 plate reader (BioTek, Winoosky, VT) every 30 min preceded by 15 seconds shaking at variable speed. Two 
biological replicates and three technical replicates were performed for every studied strain. The OD obtained 
for each strain grown on the different substrates was compared with the OD obtained in the absence of a sugar 
source. This difference in OD (Δ OD) was used as a parameter to evaluate each strain’s ability for growing on the 
different substrates.
Statistical analysis of growth. Statistical analysis of the data was carried out using SPSS for Windows, 
15.0 (SPSS Inc Chicago, IL, USA). The relationships among the maximum OD600 values of the growth on the 
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different substrates by the bifidobacteria strains were evaluated by Pearson correlation coefficients and principal 
components analysis (PCA).
Glycoprofiling. Bacterial cultures in mMRS with 2% HMO were collected at the end of the exponential 
phase and centrifuged at 12000 × g for 30 min. In the case of B. longum SC596, the samples were collected at four 
different points in the growth curve, approximately OD600nm = 0.2, 0.4, 0.6 and 0.75. At least two biological repli-
cates were performed in triplicates. Glycoprofiling was performed as in ref. 25. Supernatants were filtered using 
a multiscreen 96-well filtration plate 0.22 μ m (Millipore, Billerica, MA) prior to storage at − 80 °C. Remaining 
oligosaccharides were recovered from the supernatants (25 μ l) and reduced to their alditol forms with 1M NaBH4 
at 65 °C for 1.5 h. Each replicate was desalted by solid-phase extraction on graphitized carbon cartridges. Salts 
were removed with 6 mL of deionized water and oligosaccharides were eluted with 20% acetonitrile in water (v/v) 
and with 40% acetonitrile in 0.01% trifluoroacetic acid (v/v). Solid-phase extraction fractions were combined and 
dried under vacuum. Samples were reconstituted in 100 μ L of deionized water and diluted 50-fold for LC-MS 
analysis.
An Agilent nano-high performance liquid chromatography-chip/-time-of-flight (nano-HPLC-Chip/TOF) 
mass spectrometer equipped with a capillary pump for sample loading and a nano pump for chromatographic 
separation was used for HMO analysis. Separation was performed on a microfluidic chip equipped with an 
enrichment and nano-LC analytical column, both packed with porous graphitized carbon, using a previously 
described method12,61. Briefly, HMO were separated by a 60 min gradient using a binary solvent system consist-
ing of 3% acetonitrile/water in 0.1% formic acid (v/v) solvent A and 90% acetonitrile/water in 0.1% formic acid 
(v/v) solvent B. HMO were analyzed in positive ion mode, with a mass range between m/z 300–2000. Agilent’s 
MassHunter software was used for data acquisition and data analysis version B.03.01.
HMO monosaccharide composition was determined using accurate mass within ± 20 ppm mass error of theo-
retically calculated masses. Specific structures were assigned to HMO peaks by matching the reproducible reten-
tion time to that reported in previously annotated HMO libraries11,61. Percent consumption was calculated using 
a label-free method, employing the uninoculated HMO pool as an external standard. Total HMO consumption 
was calculated with respect to the uninoculated control by normalizing the summed abundance of all identified 
oligosaccharide spectra in ion counts in the bacterial supernatant to that of the control using equation (1):
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where API is absolute peak intensity and n is the number of identified HMO. The consumption of individual 
HMO species was quantitated in the same manner, in which the absolute peak intensity of a specific HMO struc-
ture was normalized to the peak intensity of the corresponding structure in the un-inoculated control.
Genome sequencing. B. longum SC596 was grown on MRS broth under the anaerobic conditions described 
above. Genome sequencing was performed as in ref. 53. Briefly, DNA was extracted using the MasterPure 
Gram-positive DNA Purification Kit (Epicentre), and sonicated in a Bioruptor Standard (Diagenode, Denville 
NJ). Fragmented cDNA was used to prepare a library for Illumina sequencing using the Apollo 324 Robot and the 
PrepX ILM DNA Library Kit (IntegenX, Pleasanton CA), at the Genome Center at UC Davis. Sample was ligated 
with BiooScientific Adapter 13 (Bioo Scientific, Austin TX). Finally, sample was pooled with other seven bacte-
rial genomes at the Genome Center at UC Davis DNA Technologies Core Facility, for sequencing on a Illumina 
HiSeq2500. All sequencing steps were carried out by Core personnel. Sequencing was run for 200 cycles, with 
read length of 100 bp (paired ends). Sequencing files were edited for quality using CLC-Bio Genomics Workbench 
(Cambridge, MA), and aligned to the genome sequence of B. longum DJO10A62. Resulting contigs from the 
genome of B. longum SC596 was annotated via IMG Expert Review (IMG/ER) (GOLD card: Gi17164. ER sub-
mission ID: 8631). Locus tags generated contained the BLNG prefix, and topology was linear. The gene calling 
method used was the Isolate Genome Gene Calling. Draft genome sequences were compared using the IMG/ER 
functions, and IMG/ER was also used on genomic analyses. The final draft genome of B. longum SC596 is availa-
ble at https://img.jgi.doe.gov, GOLD Project ID: Gi17164.
Clustering analysis. All the genomes were downloaded from the IMG database63. To obtain the set of 
shared and unique proteins between the genomes, an all-vs-all BlastP64 was performed, and the results were 
processed using the OrthoMCL pipeline, using an inflation value of 1.5. The results were parsed using python 
scripts (https://github.com/juanu/CompMicroGenom), which allowed us to identify the set of shared and unique 
proteins for each genome.
Phylogenomic analysis. A total of 953 single-copy gene clusters were processed to generate a phylog-
enomic tree of all the organisms. First, all clusters were aligned using Mafft65, and then checked for evidence of 
recombination using Phipack66. A total of 275 clusters were selected, and all the alignments were concatenated. 
This large alignment matrix was trimmed using Gblocks67, with a resulting alignment length of 202,423 nt. The 
phylogenetic tree was generated using FastTree (Price, Dehal, & Arkin, 2010) with the GTR model.
RNA-seq. B. longum SC596 was grown as described above in mMRS supplemented with either 2% lactose, 2% 
HMO, 2% LNT, 2% LNnT, 2% 2FL, or 2% 3FL in a microplate reader, and cultures were taken at mid-exponential 
phase OD 0.5–0.6. In the case of HMO, the samples were collected at four different points in the growth curve, 
approximately OD600 nm = 0.2, 0.4, 0.6, and 0.75. Samples were immediately pelleted at 12000 × g for 1 min and 
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stored in RNA later (Ambion). RNA extraction, ribosomal RNA depletion and cDNA conversion were performed 
as previously described53. Briefly, RNA was obtained using the Ambion RNAqeous kit (LifeTechnologies), with 
a pretreatment using 250 μ l lysozyme (50 mg/ml final; Sigma) and 125 μ l mutanolysin (1000 units/ml; Sigma), at 
37 °C for 10 min. Total RNA was immediately subjected to DNase treatment with the Turbo DNase free (Ambion) 
using 3 μ l of DNase I for 1 hour at 37 °C. RNA integrity was checked in a Bioanalyzer using an Agilent RNA 
Nano Chip, with a minimal RIN (RNA Integrity Number) of 7. Genomic DNA contamination was evaluated by 
qPCR and universal bacterial primers Uni334F and Uni514R53. Ribosomal RNA depletion was achieved using the 
Ribo-Zero magnetic kit Bacteria (Epicentre, Madison WA). Manufacturer instructions were followed (using 28 or 
26 μ l of RNA depending on the concentration). mRNA was purified with the Qiagen RNeasy Minelute Cleanup 
kit, following the instructions presented in the Ribo-Zero protocol for this part. RNA was eluted in 13 μ l. One 
μ l of the RNA was checked for removal of 16S and 23S rRNA peaks using the Qubit HS RNA Assay (Agilent). 
Chromatograms were manually inspected. Messenger RNA was finally converted to cDNA. For first strand cDNA 
synthesis, the Superscript II Reverse Transcriptase was used (Invitrogen) and second cDNA strand was synthe-
sized using the NEBNext mRNA Second Strand Synthesis Module (New England Biolabs, Ipswich, MA). Then, 
the MinElute Reaction Cleanup Kit (Qiagen, Valencia CA) was used for cleaning up the DNA. cDNA was quan-
tified using the Qubit High Sensitivity DNA kit (Life Technologies), and fragmented in a Bioruptor (Diagenode). 
An average fragment length of 300-500 bp was desired for next steps.
Sequencing libraries were prepared using the BiooScientific NEXTflex Chip Seq Kit (Bioo Scientific, Austin 
TX), similar to ref. 53. This kit is Illumina compatible and with RNA-seq applications. After Bioanalyzer and 
Qubit checks, libraries were molarly pooled and submitted to the Genome Center at UC Davis Genome Center 
DNA Technologies Core Facility, for sequencing on an Illumina HiSeq2500. All sequencing steps were carried out 
by Core personnel. Sequencing was run for 50 cycles, with read length of 50 bp (single reads). Runs were demul-
tiplexed by the UC Davis Genome Center DNA Technologies Core Facility.
Reads were processed as in ref. 53 using the CLC-Bio Genomics Workbench. Reads were trimmed setting at 
2 the maximum of ambiguous base pairs, and deleted if their quality scores were below 0.5. Edited reads were 
aligned to fasta files generated at IMG from the genome sequence (reference) of B. longum subsp. longum SC596. 
Only coding regions were considered in this analysis. Alignment allowed a maximum of 2 mismatches, and a 
maximum of 10 matches to other reads. Other settings were considered as default. The CLC-BIO tools retrieved 
information regarding the gene length, total and unique gene reads aligning to a specific locus tag, and auto-
matically calculated the RPKM value (Reads Per Kilobase per Million mapped reads). Statistical analysis such 
as hierarchical clustering were performed using RPKM data for each sample as in ref. 53, as well as Differential 
Expression determination using the R package “DESeq” and Gene Set Enrichment Analysis. The data from the 
B. longum SC596 RNA-sequencing studies are available in the NCBI Gene Expression Omnibus database (http://
www.ncbi.nlm.nih.gov/geo/) with accession number GSE87697.
Gene cloning and protein expression. Gene sequences were analyzed using the Integrated Microbial 
Genomes (IMG) database. For glycosyl hydrolase coding genes, primers were designed with modifications for 
cloning using the pEco-T7-cHis cloning kit (Gentarget Inc) and for SBP coding genes, primers were designed 
with modifications for cloning using the pEco-T7-nGST cloning kit (Gentarget Inc) Primer sequences are 
shown in Table S9. Genomic DNA from B. longum SC596 was purified from a 1 ml culture using the Qiagen 
DNeasy Blood & Tissue Kit following the manufacturer’s instructions for purification of Gram Positive bac-
terial DNA. BLNG_01753, BLNG_01264, and BLNG_01263 genes were amplified by PCR using 0.8 uM of 
each forward and reverse primer (Table S9), 42 ng genomic DNA, 0.2 mM GeneAmp deoxynucleotide triphos-
phate mix (Applied Biosystems, Foster City, CA), and 0.5 U of Phusion High-Fidelity DNA Polymerase (New 
England Biolabs, Ipswich, MA) in a 25 μ l final volume. BLNG_00015 was amplified by PCR using 0.75 uM of 
each forward and reverse primer, 86 ng genomic DNA, 0.18 mM GeneAmp deoxynucleotide triphosphate mix 
(Applied Biosystems, Foster City, CA), and 1 U of Phusion High-Fidelity DNA Polymerase (New England Biolabs, 
Ipswich, MA) in a 53 μ l final volume. For glycosyl hydrolases, BLNG_01753, BLNG_01264, and BLNG_01263, 
PCR was conducted with initial denaturation of 98 °C for 30 s and 35 cycles of denaturation of 98 °C for 10 s, 
annealing at 63 °C for 30 sec, extension at 72 °C for 1 min 15 s, and a final extension of 72 °C for 10 min using an 
Applied Biosystems Verti 96 well thermocycler (Applied Biosystems, Foster City, CA). For glycosyl hydrolase 
BLNG_00015, an annealing temperature of 68 °C was used. Annealing for SBPs BLNG_00160, BLNG_00936 and 
BLNG_01257 was 63 °C. A total volume of 225 μ l of PCR products encoding glycosyl hydrolases were gel purified 
and cloned into pEco-T7-cHis vectors. A volume of 100 μ l of PCR products, encoding solute binding proteins, 
were gel-purified and cloned into pEco-T7-nGST vectors. Recombinant BL21 Star clones were confirmed via 
plasmid sequencing of the insert. Sequencing primers IC-1006-fwd and IC-1006-rev were used for pEco-T7-cHis 
vectors and primers IC-1004-fwd and IC-1004-rev were used for pEco-T7-nGST vectors. Furthermore, for plas-
mid inserts containing glycosyl hydrolases, intermediate primers were designed to fully sequence the glycosyl 
hydrolase insert. For recombinant E. coli BL21 Star cultures with inserts (Blng_01257-nGST, Blng_00160-nGST, 
Blng_00936-nGST, and Blng_01263-cHis), protein expression was conducted using 200 ml of LB supplemented 
with 100 ug/ml carbenicillin. For protein expression of recombinant E. coli BL21 Star cultures with inserts 
(Blng_01264-cHis and Blng_00015-cHis) 700 ml of LB with 100 ug/ml carbenicillin were used, and for recombi-
nant E. coli BL21 Star cultures with insert (Blng_01753-cHis) 600 ml of LB with 100 ug/ml carbenicillin was used. 
Cells were grown in a shaker at 250 rpm (Innova-4000 incubation shaker; New Brunswick Scientific, Edison, NJ) 
until they reached an OD of 0.5 and then protein synthesis was induced with a final concentration of 0.5 mM 
isopropyl-β -d-thiogalactopyranoside (IPTG) overnight, with the exception of recombinant clon E. coli BL21 Star 
Blng_01263-cHis, which was induced for seven hours. E. coli BL21 Star cultures with plasmid inserts encoding 
glycosyl hydrolases were induced at 28 °C and E. coli BL21 Star cultures with plasmid inserts encoding solute 
binding proteins were induced at room temperature. Immediately following induction, recombinant E. coli BL21 
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Star cultures were centrifuged at 4000 rpm on an Eppendorf 5804 centrifuge (Hauppauge, NY) for 20 min. at 
4 °C and were frozen at − 80 °C. Pellets were suspended in Bugbuster protein extraction reagent (EMD chem-
icals) using 5 ml Bugbuster for 50 ml E. coli culture. For Bugbuster suspended recombinant E. coli BL21 Star 
cultures with GST tagged SBP inserts (Blng_00160-nGST, and Blng_00936-nGST, Blng_01257-nGST), 30 μ l of 
DNAse I (Roche) from a 10 U/μ l stock and 30 μ l of lysozyme from a 100 mg/ml stock were added per 20 ml of 
Bugbuster suspended culture. Following inversion and a five minute incubation, the suspension was centrifuged 
twice for 15 min. at 13200 rpm at 4 °C, and the supernatant was applied to a 1 ml Bio-Scale Mini Profinity GST 
column attached to a EP-1 Econo Pump (Bio-rad, Hercules, CA). For purification of the SBPs Blng_01257-nGST, 
Blng_00160-nGST, Blng_00936-nGST the final step was the exchange of glutathione with PBS using 30 kDa cut-
off Amicon Ultra-15 centrifugal units (Millipore, Billerica, CA). For Bugbuster suspended recombinant E. coli 
BL21 Star cultures with histidine (His) tagged glycosyl hydrolase inserts (Blng_00015-cHis, Blng_1263-cHis, 
Blng_1264-cHis, and Blng_01753-cHis), 60 μ l of DNAse I (Roche) from a 10 U/μ l stock and 120 μ l of lysozyme 
from a 50 mg/ml stock were added per 20 ml of Bugbuster suspended culture with the exception of recombi-
nant Blng_01753-cHis where 180 μ l of lysozyme was added. Following inversion and a five minute incubation, 
the suspension was centrifuged for 30 min. at 13200 rpm at 4 °C, and the supernatant was applied to a 1 ml 
Bio-Scale Mini Profinity immobilized-metal affinity chromatography column attached to a EP-1 Econo Pump 
(Bio-rad, Hercules, CA. For purification of the glycosyl hydrolases the final step was the exchange of imidazole 
with PBS using 10 kDa cutoff Amicon Ultra-15 centrifugal units (Millipore, Billerica, CA) with the exception of 
(Blng_01263-cHis) where a 30 kDa cutoff Amicon Ultra-15 centrifugal unit was used (Millipore, Billerica, CA). 
Recombinant proteins were checked for purity and the correct size on 4–15% SDS-PAGE gels.
Glycan array. GST-tagged family 1 SBPs were screened by the Core H of the Consortium for Functional 
Glycomics against Version 5.1 of the Mammalian Glycan Array to examine for glycan interaction. SBPs were 
diluted to a protein concentration of 200 ug/ml in binding buffer and assayed. The binding buffer composition 
was 20 mM Tris-HCl pH 7.4, 150 mM sodium chloride, 2 mM calcium chloride, 2 mM magnesium chloride, 
0.05% Tween 20, and 1% BSA. An anti-GST Alexa 488 antibody was used for binding and detection of protein on 
the array. The results were expressed in relative fluorescent units (RFU). Six replicates were carried out and the 
highest and lowest point from each set of replicates was removed.
Optimum enzyme conditions. To measure activity for β -galactosidases, the OD420 was measured using a 
96 well microplate using an Eon microplate reader (BioTek) in a total assay volume of 100 μ l with 1 mg/ml final 
concentration ONPG (2-Nitrophenyl-β -D-galactopyranoside; Sigma-Aldrich). To measure α -fucosidase activ-
ity, the OD405 was measured using a 96 well microplate using an Eon microplate reader (BioTek) in a total assay 
volume of 100 μ l with 2 mg/ml final concentration CNP-fucose (2-chloro-4-nitrophenyl-α -L-fucopyranoside; 
Carbosynth, Berkshire, United Kingdom). To determine pH optimum for BLNG_00015, BLNG_01264, and 
BLNG_01753, McIlvaine buffers were prepared within the pH range of 4–8 to determine at temperature 37 °C 
using the above conditions. The optimum temperature for enzyme activity for BLNG_00015, BLNG_01264, and 
BLNG_01753 was found by incubating the purified enzyme at optimum pH in temperatures 20, 30, 37, 45, 55, 
and 65 °C in a 100 μ l total assay volume using conditions similar as those used to determine pH optimum. For 
BLNG_00015, 0.001 mg of protein was used to examine both temperature and pH optimum. For BLNG_01753, 
0.001 mg was used to examine pH optimum, and 0.0006 mg of protein was used to examine the temperature 
optimum. The time of incubation for BLNG_00015, BLNG_01264, and BLNG_01753 was 1.5 min, 6 min and 30 s 
respectively. For pH and temperature assays, reactions were terminated by either the addition of an equal volume 
of 1 M Na2CO3 or for certain assays boiling at 95 °C for 2 minutes. Reactions were all terminated using the same 
method for a particular enzyme assay.
Mass spectrometry analysis of enzyme digestions. Enzyme Digestion. Purified recombinant enzymes 
were stored at − 80 °C until analysis. A reduced human milk oligosaccharide (HMO) pool (1.5 μ L, 5 mg/mL) 
was combined with 3 μ L of each enzyme and 5.5 μ L of 0.1 M ammonium acetate buffer. Incubation conditions 
were specific for each enzyme based on optimum pH and temperature values previously determined. BLNG_1264 
reaction was performed at pH 7.0 and 45 °C for 1 and 3 hours using 1 mg/ml of enzyme. BLNG_00015 and 
BLNG_01753 incubations with HMO were performed at 55 °C for 1 hour using 3 μ L 2 mg/ml of enzyme, at pH 6.0 
for BLNG_00015, and 5.5 for BLNG_01753. For BLNG_1263 assay was carried out at pH 5 and 37 °C for 3 hours 
using 0.06 mg of enzyme using 1.5 uL of enzyme, 1.5 uL of HMO pool, and 7 uL of ammonium acetate buffer.
Nano-HPLC-Chip/TOF Mass Spectrometry. Analysis of the digested HMO was performed on a nano-HPLC- 
Chip/TOF MS system. Liquid chromatography is done on an Agilent 1200 series unit which incorporates a 
capillary pump for sample loading at a flow rate of 4.0 μ L/min and 1 μ L injection volume, and an analytical 
pump for analyte separation. A binary gradient was used for separation, with aqueous solvent A (3% acetoni-
trile:water (v/v) in 0.1% formic acid) and organic solvent B (90% acetonitrile:water (v/v) in 0.1% formic acid). 
Loading and separation was achieved on a microfluidic chip, which contains a 40 nL enrichment column and a 
75 μ L × 43 mm analytical column packed with porous graphitized carbon. The unit is coupled to an Agilent 6220 
series time-of-flight mass spectrometer via chip-cube interface. Data was collected in the positive mode, and the 
instrument was calibrated with a dual nebulizer electrospray source and internal calibrant ions ranging from m/z 
118.086 to 2721.895. The method developed for separating HMO mixtures by Wu et al. was used12.
Data Processing. Data was collected and analyzed using Agilent MassHunter Qualitative Analysis software, ver-
sion B.03.01. The Find by Molecular Feature function was used to identify HMO compounds, and an in-house 
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program was used for peak alignment. Specific structures were identified and assigned by matching exact mass, 
within 20 ppm mass error, and retention time to previously developed annotated HMO libraries11,12. Absolute 
abundances as extracted in ion counts were directly correlated to the abundance of that compound. To calculate 
the consumption of specific structures, an undigested HMO pool was run along with the digested HMO samples. 
The abundance of structures extracted from the undigested pool were compared to those from the digested pool 
using equation (2):
=




−



.
.







×consumed Abund digested pool
Abund undigested pool
% 1 100
(2)
Twenty-two distinctive structures were identified. If there were two closely eluting peaks and the isomer abun-
dances could not be integrated separately, those peak abundances were summed and the two isomers grouped 
together.
References
1. Sekirov, I., Russell, S. L., Antunes, L. C. M. & Finlay, B. B. Gut Microbiota in Health and Disease. Physiological Reviews 90, 859–904 
(2010).
2. Dominguez-Bello, M. G., Blaser, M. J., Ley, R. E. & Knight, R. Development of the Human Gastrointestinal Microbiota and Insights 
From High-Throughput Sequencing. Gastroenterology 140, 1713–1719 (2011).
3. Zeissig, S. & Blumberg, R. S. Life at the beginning: perturbation of the microbiota by antibiotics in early life and its role in health and 
disease. Nat Immunol 15, 307–310 (2014).
4. Scholtens, P. A., Oozeer, R., Martin, R., Amor, K. B. & Knol, J. The early settlers: intestinal microbiology in early life. Annu Rev Food 
Sci Technol 3, 425–447 (2012).
5. Kalliomaki, M., Collado, M. C., Salminen, S. & Isolauri, E. Early differences in fecal microbiota composition in children may predict 
overweight. Am J Clin Nutr 87, 534–538 (2008).
6. Lin, A. et al. Distinct Distal Gut Microbiome Diversity and Composition in Healthy Children from Bangladesh and the United 
States. PLoS ONE 8, e53838 (2013).
7. Bäckhed, F. et al. Dynamics and Stabilization of the Human Gut Microbiome during the First Year of Life. Cell Host & Microbe 17, 
690–703 (2014).
8. Smilowitz, J. T. et al. The Human Milk Metabolome Reveals Diverse Oligosaccharide Profiles. The Journal of nutrition 143, 
1709–1718 (2013).
9. Rogier, E. W. et al. Secretory antibodies in breast milk promote long-term intestinal homeostasis by regulating the gut microbiota 
and host gene expression. Proceedings of the National Academy of Sciences 111, 3074–3079 (2014).
10. De Leoz, M. L. et al. Lacto-N-tetraose, fucosylation, and secretor status are highly variable in human milk oligosaccharides from 
women delivering preterm. J Proteome Res 11, 4662–4672 (2012).
11. Wu, S., Grimm, R., German, J. B. & Lebrilla, C. B. Annotation and structural analysis of sialylated human milk oligosaccharides. J 
Proteome Res 10, 856–868 (2011).
12. Wu, S., Tao, N., German, J. B., Grimm, R. & Lebrilla, C. B. Development of an annotated library of neutral human milk 
oligosaccharides. J Proteome Res 9, 4138–4151, doi: 10.1021/pr100362f (2010).
13. Ninonuevo, M. R. et al. A strategy for annotating the human milk glycome. Journal of agricultural and food chemistry 54, 7471–7480 
(2006).
14. Kunz, C., Rudloff, S., Baier, W., Klein, N. & Strobel, S. Oligosaccharides in human milk: structural, functional, and metabolic aspects. 
Annu Rev Nutr 20, 699–722 (2000).
15. Yatsunenko, T. et al. Human gut microbiome viewed across age and geography. Nature 486, 222–227 (2012).
16. Roger, L. C. & McCartney, A. L. Longitudinal investigation of the faecal microbiota of healthy full-term infants using fluorescence 
in situ hybridization and denaturing gradient gel electrophoresis. Microbiology 156, 3317–3328 (2010).
17. Turroni, F. et al. Diversity of bifidobacteria within the infant gut microbiota. PLoS One 7, e36957 (2012).
18. Avershina, E. et al. Bifidobacterial succession and correlation networks in a large unselected cohort of mothers and their children. 
Applied and environmental microbiology 79, 497–507 (2013).
19. Garrido, D., Dallas, D. C. & Mills, D. A. Consumption of human milk glycoconjugates by infant-associated bifidobacteria: 
mechanisms and implications. Microbiology 159, 649–664 (2013).
20. Garrido, D., Kim, J. H., German, J. B., Raybould, H. E. & Mills, D. A. Oligosaccharide binding proteins from Bifidobacterium 
longum subsp. infantis reveal a preference for host glycans. PLoS One 6, e17315 (2011).
21. Yoshida, E. et al. Bifidobacterium longum subsp. infantis uses two different beta-galactosidases for selectively degrading type-1 and 
type-2 human milk oligosaccharides. Glycobiology 22, 361–368 (2012).
22. Sela, D. A. et al. Bifidobacterium longum subsp. infantis ATCC 15697 alpha-fucosidases are active on fucosylated human milk 
oligosaccharides. Applied and environmental microbiology 78, 795–803 (2012).
23. Sela, D. A. et al. An infant-associated bacterial commensal utilizes breast milk sialyloligosaccharides. J Biol Chem 286, 11909–11918 
(2011).
24. Garrido, D., Ruiz-Moyano, S. & Mills, D. A. Release and utilization of N-acetyl-d-glucosamine from human milk oligosaccharides 
by Bifidobacterium longum subsp. infantis. Anaerobe 18, 430–435 (2012).
25. Ruiz-Moyano, S. et al. Variation in Consumption of Human Milk Oligosaccharides by Infant Gut-Associated Strains of 
Bifidobacterium breve. Applied and environmental microbiology 79, 6040–6049 (2013).
26. Ashida, H. et al. Two distinct alpha-L-fucosidases from Bifidobacterium bifidum are essential for the utilization of fucosylated milk 
oligosaccharides and glycoconjugates. Glycobiology 19, 1010–1017 (2009).
27. Kiyohara, M. et al. An exo-alpha-sialidase from bifidobacteria involved in the degradation of sialyloligosaccharides in human milk 
and intestinal glycoconjugates. Glycobiology 21, 437–447 (2011).
28. Turroni, F. et al. Genome analysis of Bifidobacterium bifidum PRL2010 reveals metabolic pathways for host-derived glycan foraging. 
Proceedings of the National Academy of Sciences of the United States of America 107, 19514–19519 (2010).
29. Frese, S. A., Parker, K., Calvert, C. C. & Mills, D. A. Diet shapes the gut microbiome of pigs during nursing and weaning. Microbiome 
3, 1–10 (2015).
30. Huang, Y.-L., Chassard, C., Hausmann, M., von Itzstein, M. & Hennet, T. Sialic acid catabolism drives intestinal inflammation and 
microbial dysbiosis in mice. Nat Commun 6, doi: 10.1038/ncomms9141 (2015).
31. Charbonneau, Mark R. et al. Sialylated Milk Oligosaccharides Promote Microbiota-Dependent Growth in Models of Infant 
Undernutrition. Cell 164, 859–871 (2016).
32. Egan, M. et al. Cross-feeding by Bifidobacterium breve UCC2003 during co-cultivation with Bifidobacterium bifidum PRL2010 in 
a mucin-based medium. BMC Microbiology 14, 1–14 (2014).
www.nature.com/scientificreports/
17Scientific RepoRts | 6:35045 | DOI: 10.1038/srep35045
33. Sela, D. A. et al. The genome sequence of Bifidobacterium longum subsp. infantis reveals adaptations for milk utilization within the 
infant microbiome. Proceedings of the National Academy of Sciences of the United States of America 105, 18964–18969 (2008).
34. O’Callaghan, A., Bottacini, F., O’Connell Motherway, M. & van Sinderen, D. Pangenome analysis of Bifidobacterium longum and 
site-directed mutagenesis through by-pass of restriction-modification systems. BMC Genomics 16, 1–19 (2015).
35. LoCascio, R. G., Desai, P., Sela, D. A., Weimer, B. & Mills, D. A. Broad conservation of milk utilization genes in Bifidobacterium 
longum subsp. infantis as revealed by comparative genomic hybridization. Applied and environmental microbiology 76, 7373–7381 
(2010).
36. Sela, D. A. & Mills, D. A. Nursing our microbiota: molecular linkages between bifidobacteria and milk oligosaccharides. Trends 
Microbiol 18, 298–307 (2010).
37. LoCascio, R. G. et al. Glycoprofiling of bifidobacterial consumption of human milk oligosaccharides demonstrates strain specific, 
preferential consumption of small chain glycans secreted in early human lactation. Journal of agricultural and food chemistry 55, 
8914–8919 (2007).
38. Asakuma, S. et al. Physiology of consumption of human milk oligosaccharides by infant gut-associated bifidobacteria. J Biol Chem 
286, 34583–34592 (2011).
39. LoCascio, R. G. et al. A versatile and scalable strategy for glycoprofiling bifidobacterial consumption of human milk oligosaccharides. 
Microbial Biotechnology 2, 333–342 (2009).
40. Delétoile, A. et al. Species delineation and clonal diversity in four Bifidobacterium species as revealed by multilocus sequencing. 
Research in Microbiology 161, 82–90 (2010).
41. Fukuda, S. et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 469, 543–547 
(2011).
42. Ruas-Madiedo, P., Gueimonde, M., Fernandez-Garcia, M., de los Reyes-Gavilan, C. G. & Margolles, A. Mucin degradation by 
Bifidobacterium strains isolated from the human intestinal microbiota. Applied and environmental microbiology 74, 1936–1940 
(2008).
43. Fujita, K. et al. Identification and molecular cloning of a novel glycoside hydrolase family of core 1 type O-glycan-specific endo-
alpha-N-acetylgalactosaminidase from Bifidobacterium longum. J Biol Chem 280, 37415–37422 (2005).
44. Parche, S. et al. Lactose-over-glucose preference in Bifidobacterium longum NCC2705: glcP, encoding a glucose transporter, is 
subject to lactose repression. Journal of bacteriology 188, 1260–1265 (2006).
45. Kim, T. B. et al. Quantitative comparison of lactose and glucose utilization in Bifidobacterium longum cultures. Biotechnol Prog 19, 
672–675 (2003).
46. Nishimoto, M. & Kitaoka, M. Identification of N-acetylhexosamine 1-kinase in the complete lacto-N-biose I/galacto-N-biose 
metabolic pathway in Bifidobacterium longum. Applied and environmental microbiology 73, 6444–6449 (2007).
47. De Bruyn, F., Beauprez, J., Maertens, J., Soetaert, W. & De Mey, M. Unraveling the Leloir Pathway of Bifidobacterium bifidum: 
Significance of the Uridylyltransferases. Applied and Environmental Microbiology 79, 7028–7035 (2013).
48. Garrido, D. et al. Endo-beta-N-acetylglucosaminidases from Infant Gut-associated Bifidobacteria Release Complex N-glycans from 
Human Milk Glycoproteins. Mol Cell Proteomics 11, 775–785 (2012).
49. Garrido, D. et al. Utilization of galactooligosaccharides by Bifidobacterium longum subsp. infantis isolates. Food Microbiology 33, 
262–270 (2013).
50. Yu, H. et al. Genome Sequence of the Bacterium Bifidobacterium longum Strain CMCC P0001, a Probiotic Strain Used for Treating 
Gastrointestinal Disease. Genome Announcements 1, e00716–13 (2013).
51. Schell, M. A. et al. The genome sequence of Bifidobacterium longum reflects its adaptation to the human gastrointestinal tract. 
Proceedings of the National Academy of Sciences of the United States of America 99, 14422–14427 (2002).
52. Gonzalez, R., Klaassens, E. S., Malinen, E., de Vos, W. M. & Vaughan, E. E. Differential transcriptional response of Bifidobacterium 
longum to human milk, formula milk, and galactooligosaccharide. Applied and environmental microbiology 74, 4686–4694 (2008).
53. Garrido, D. et al. Comparative transcriptomics reveals key differences in the response to milk oligosaccharides of infant gut-
associated bifidobacteria. Scientific Reports 5, 13517 (2015).
54. Suzuki, R. et al. Structural and thermodynamic analyses of solute-binding Protein from Bifidobacterium longum specific for core 1 
disaccharide and lacto-N-biose I. J Biol Chem 283, 13165–13173 (2008).
55. Sakurama, H. et al. Lacto-N-biosidase Encoded by a Novel Gene of Bifidobacterium longum Subspecies longum Shows Unique 
Substrate Specificity and Requires a Designated Chaperone for Its Active Expression. Journal of Biological Chemistry 288, 
25194–25206 (2013).
56. Wada, J. et al. Bifidobacterium bifidum Lacto-N-Biosidase, a Critical Enzyme for the Degradation of Human Milk Oligosaccharides 
with a Type 1 Structure. Applied and environmental microbiology 74, 3996–4004 (2008).
57. Pickard, J. M. et al. Rapid fucosylation of intestinal epithelium sustains host-commensal symbiosis in sickness. Nature 514, 638–641 (2014).
58. Pacheco, A. R. et al. Fucose sensing regulates bacterial intestinal colonization. Nature 492, 113–117 (2012).
59. Thompson, J. D., Higgins, D. G. & Gibson, T. J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment 
through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic acids research 22, 4673–4680 (1994).
60. Ward, R. E., Ninonuevo, M., Mills, D. A., Lebrilla, C. B. & German, J. B. In vitro fermentation of breast milk oligosaccharides by 
Bifidobacterium infantis and Lactobacillus gasseri. Applied and environmental microbiology 72, 4497–4499 (2006).
61. Totten, S. M. et al. Comprehensive Profiles of Human Milk Oligosaccharides Yield Highly Sensitive and Specific Markers for 
Determining Secretor Status in Lactating Mothers. Journal of proteome research 11, 6124–6133 (2012).
62. Lee, J. H. et al. Comparative genomic analysis of the gut bacterium Bifidobacterium longum reveals loci susceptible to deletion 
during pure culture growth. BMC Genomics 9, 247 (2008).
63. Markowitz, V. M. et al. The integrated microbial genomes (IMG) system. Nucleic Acids Res 34, D344–D348 (2006).
64. Altschul, S. F. et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Research 
25, 3389–3402 (1997).
65. Katoh, K. & Toh, H. Recent developments in the MAFFT multiple sequence alignment program. Briefings in Bioinformatics 9, 
286–298 (2008).
66. Bruen, T. C., Philippe, H. & Bryant, D. A Simple and Robust Statistical Test for Detecting the Presence of Recombination. Genetics 
172, 2665–2681 (2006).
67. Castresana, J. Selection of Conserved Blocks from Multiple Alignments for Their Use in Phylogenetic Analysis. Molecular Biology 
and Evolution 17, 540–552 (2000).
Acknowledgements
The authors thank the Consortium of Functional Glycomics (Core H), Dr. David F. Smith and Dr. Jamie 
Heimburg-Molinaro for their collaboration in this work and excellent work on the Glycan Array experiments. 
This work was funded National Institutes of Health Awards AT007079, HD065122 and AT008759, and the Peter 
J. Shields Endowed Chair in Dairy Food Science. DG was supported by the Conicyt Fondecyt de Iniciacion grant 
11130518. SRM was supported by the Ministry of Education and Science of Spain and University of Extremadura, 
Spain.
www.nature.com/scientificreports/
1 8Scientific RepoRts | 6:35045 | DOI: 10.1038/srep35045
Author Contributions
Performed the experiments: D.G., S.R.M., N.K., D.G.L., J.U., J.D. and S.T. Analyzed the data: D.G., S.R.M., N.K., 
D.G.L., J.U., J.D., S.T. and Wrote the manuscript: D.G. Provided materials: C.B.L., J.B.G. and D.A.M. Conceived 
the study: D.G. and D.A.M. All authors read and approved the final manuscript.
Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep
Competing financial interests: J.B.G., C.B.L. and D.A.M., are co-founders of Evolve Biosystems, Inc., a 
company focused on diet-based manipulation of the gut microbiota.
How to cite this article: Garrido, D. et al. A novel gene cluster allows preferential utilization of fucosylated milk 
oligosaccharides in Bifidobacterium longum subsp. longum SC596. Sci. Rep. 6, 35045; doi: 10.1038/srep35045 (2016).
This work is licensed under a Creative Commons Attribution 4.0 International License. The images 
or other third party material in this article are included in the article’s Creative Commons license, 
unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, 
users will need to obtain permission from the license holder to reproduce the material. To view a copy of this 
license, visit http://creativecommons.org/licenses/by/4.0/
 
© The Author(s) 2016
